This is a promotional email intended for UK Healthcare Professionals, sent on behalf of Takeda UK Limited. Prescribing Information and Adverse Event reporting can be found at the bottom of this email. Problems viewing this email? View it in your browser. for hereditary angioedema (HAE) therapies Takeda-funded homecare service Takeda provides a fully funded, patient-centred homecare service for its HAE therapies – TAKHZYRO®▼ (lanadelumab), FIRAZYR® (icatibant) and Cinryze®▼ (Human C1-esterase inhibitor). This homecare service is offered as part of a package deal and is fully funded by Takeda UK Ltd. NHS-funded homecare provisions are not under the control of Takeda UK Ltd and may differ in their offering. Speak to our Divisional Sales Director Immunology & HAE, Paul Springthorpe to discuss homecare for Takeda HAE products: Please click YES if you would like to speak to Paul Springthorpe about the Takeda HAE Homecare service. YES (By selecting YES you are confirming you are happy for your contact details to be disclosed by Data4NHS with Takeda solely to fulfil this request and to be retained for no longer than necessary for this purpose) Once a suitable patient has been identified, the steps below are followed to initiate the patient at home: Benefits to patients from the homecare service include: • Comprehensive training to aid competency in self-administration so that the patient can be signed off as independent • Individual support in homecare setting • Confidence that HCP retains duty of care, whilst having visibility of service performance and medication compliance TAKHZYRO® (lanadelumab) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older1 You can learn more about the Homecare service for TAKHZYRO here: Find out about the Takhzyro Homecare service (Clicking this button takes you to Takeda promotional content hosted on BMJ.com) TAKHZYRO is an effective medication clinically proven to significantly reduce HAE attacks, with many patients achieving prolonged periods of ZERO attacks.1-3 (n=212, 81.8% pts attack free for ≥6 months & 68.9% pts attack free for ≥12 months). Primary efficacy end point was the number of investigator-confirmed attacks of hereditary angioedema over the treatment period.2 Convenient administration for patients TAKHZYRO is a subcutaneous injection which can be self-administered using a pre-filled syringe (recommended starting dose 300 mg Q2W).1 Generally acceptable tolerability profile The most common adverse reactions with TAKHZYRO were injection-site reactions, of which 90% resolved within 1 day, with a median duration of 6 minutes.1* Other common adverse reactions were hypersensitivity, dizziness, rash maculo-palpular, myalgia, Alanine aminotransferase increased and Aspartate aminotransferase increases were observed.1 Improved patient QoL TAKHZYRO can improve patient QoL, with a clinically meaningful improvement in AE-QoL in both HELP-03* and HELP OLE†.1-3 • HELP-03: The mean change in AE-QoL total score from baseline for TAKHZYRO 300 mg Q2W was -20 vs -5 with placebo.‡1,2 • HELP OLE: The mean change in AE-QoL total score from baseline was -10 and -20 for rollovers and nonrollovers, respectively.3 Explore the real-world evidence for TAKHZYRO (Clicking this button takes you to Takeda promotional content hosted on BMJ.com) TAKHZYRO can be self-administered or administered by a caregiver only after training on subcutaneous injection technique by a healthcare professional.1 Training on the subcutaneous injection technique can be initiated at home by a homecare nurse rather than in clinic. *The HELP-03 study was an international, randomised, double-blind, Phase 3 study of 125 patients with HAE over 26 weeks. Patients were randomised to receive TAKHZYRO 300 mg Q2W (n=27), TAKHZYRO 300 mg Q4W (n=29), TAKHZYRO 150 mg Q4W (n=28) or placebo (n=41).2 † The HELP OLE study was a Phase 3 open-label extension to the HELP-03 study, consisting of patients who completed the randomised, double-blind study (rollovers) and additional patients who were not part of the HELP-03 study (non-rollovers). All patients received open-label TAKHZYRO 300 mg Q2W over a mean treatment period of 29.6 months (range 1.4–34.2 months), followed by a 4-week safety follow-up before discharge from the study. The primary endpoint of HELP OLE was to evaluate long-term safety of repeated TAKHZYRO dosing.3 ‡All data are least squares (LS) mean change from baseline to Week 26 across TAKHZYRO treatment arms vs placebo.1 These findings are tertiary endpoint analyses and therefore require further investigation to corroborate the findings. Abbreviations AE-QoL, angioedema quality of life; HAE, hereditary angioedema; OLE, open-label extension; Q2W, every 2 weeks; Q4W, every 4 weeks; QoL, quality of life. References 1. TAKHZYRO® Summary of Product Characteristics [GB & NI]. 2. Banerji A, et al. JAMA. 2018;320:2108–2121. 3. Banerji A, et al. Allergy. 2022;77:979–990. ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com Click here for TAKHZYRO Prescribing Information Click here for FIRAZYR Prescribing Information Click here for Cinryze Prescribing Information Job code: C-APROM/GB/TAKH/0137 Date of preparation: August 2023 ©2023 Takeda UK Limited. All rights reserved. TAKHZYRO® is a registered trademark of Dyax Corp. Takeda® and the Takeda Logo® are registered trademarks of Takeda Pharmaceutical Company Limited. Takeda UK Limited, 1 Kingdom Street, London, W2 6BD, United Kingdom. This email has been forwarded to you by Data4NHS on behalf of Takeda UK Limited. Manage your Data4NHS profile by submitting your changes HERE. View our privacy policy HERE. UNSUBSCRIBE